Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06886516 · ClinicalTrials.gov registry record · Early Phase 1
Apixaban in Thrombocytopenia
A Early Phase 1 study of Deep Vein Thrombosis and Thrombocytopenia, sponsored by Rushad Patell.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06886516 is a Early Phase 1 study of Deep Vein Thrombosis and Thrombocytopenia that is actively recruiting participants, run by Rushad Patell. The registered enrollment target is 30 participants, below the 7,930-participant average among 24 other Deep Vein Thrombosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06886516, a Early Phase 1 study of Deep Vein Thrombosis and Thrombocytopenia, is actively recruiting participants, sponsored by Rushad Patell.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes. The name of the study drug involved in this study is: -Apixiban (a type of anticoagulant)
Conditions Studied
Interventions
- DRUG Apixaban
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2028-07-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06886516
The ClinicalTrials.gov registry entry for NCT06886516 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,930-participant average among 24 other Deep Vein Thrombosis trials with a reported enrollment target (100% lower). The listed sponsor is Rushad Patell, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Deep Vein Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Apixaban is the first listed.
NCT06886516 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06886516 about?
NCT06886516 is a clinical study titled "Apixaban in Thrombocytopenia". This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see...
What is the current status of trial NCT06886516?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-02-28. Estimated completion is 2028-07-01.
What conditions does trial NCT06886516 study?
This clinical trial studies the following conditions: Deep Vein Thrombosis, Thrombocytopenia, Pulmonary Embolism and Thrombosis, Recurrent Venous Thromboembolism.
What interventions are being tested in trial NCT06886516?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT06886516?
This trial is sponsored by Rushad Patell, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06886516 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Deep Vein Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Non-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression.
RECRUITING
-
Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection
RECRUITING · NA
-
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
ACTIVE NOT RECRUITING · NA
-
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.